In addition to BRAF mutations, RET chromosomal rearrangements also activate the mitogen-activated protein kinase (MAPK) pathway, contributing to tumorigenesis [30], particularly in cases of PTC with HT. The gene discussed is BRAF; the disease is hematocrit.